CRISPR Therapies Go Mainstream in 2026

Starting from Casgevy, gene-editing therapy is expanding from sickle cell into other inherited diseases and cancer. We map the status and the next walls: price and in vivo editing.

KIYODO2026-06-1000

#CRISPR#Gene editing#Gene therapy#Casgevy#Medicine

A few years after the 2020 Nobel Prize in Chemistry, CRISPR has finally crossed from "research tool" to "approved therapy." Starting from the 2023–2024 approval of the world's first CRISPR medicine, Casgevy, in the US and Europe, 2026 is a phase of expanding indications and fresh approvals. This piece maps where gene-editing therapy stands and what comes next.

The short version

Led by Casgevy, indications are spreading from sickle cell disease toward other inherited diseases and cancer.
The biggest wall isn't the technology but the price — multi-million-dollar one-time costs block broad access.
The next frontier is the shift from ex vivo to in vivo editing — treatments that work with a single infusion.

The road Casgevy opened

The emblem of CRISPR therapy is Casgevy (exagamglogene autotemcel). It treats sickle cell disease and transfusion-dependent beta-thalassemia. It's an ex vivo therapy: the patient's own blood stem cells are removed, edited with CRISPR-Cas9, and returned.

The mechanism is elegant. Rather than directly repairing the disease gene, it edits a switch (the BCL11A gene) to reawaken fetal hemoglobin produced in the womb. One treatment can deliver durable improvement; in trials many patients became transfusion-free with vaso-occlusive crises eliminated.

Indications expanding to cancer and beyond

The 2026 focus is indication expansion. With safety and efficacy established in sickle cell disease, CRISPR's range is widening to other single-gene disorders (hereditary angioedema, familial hypercholesterolemia, and more).

In oncology, combinations with CAR-T therapy — editing a patient's T cells to attack tumors more effectively — are advancing. "Next-generation CAR-T," using CRISPR to edit several genes at once for better efficacy and safety, is in clinical stages at multiple companies. Application to hard-to-treat solid tumors is still early, but the direction is clear.

The biggest wall is price, not science

The central challenge is no longer "does it work" but "can you pay for it." Casgevy is priced at roughly $2.2 million per treatment in the US — extraordinarily high even for a one-time cure.

The reason is manufacturing complexity. Ex vivo editing requires bespoke production per patient: extract stem cells, edit, verify quality, reinfuse. Economies of scale barely apply. Reimbursement frameworks and outcomes-based payment (pay only if it works) are key levers for access.

The next prize: in vivo editing

The technical frontier is in vivo editing. Instead of removing cells as Casgevy does, the editing tools are delivered directly into the body to rewrite the genome in the target organ. Lipid-nanoparticle (LNP) delivery to the liver leads the way, with trials advancing in conditions like familial hypercholesterolemia.

If in vivo editing matures, manufacturing costs fall dramatically and a "gene therapy in a single infusion" comes into view. This is speculation, but it could collapse the price wall outright. The flip side: an in-body edit can't be undone, so off-target safety validation must be even stricter than for ex vivo.

Bottom line

In 2026 CRISPR therapy is an approved reality. The sickle cell success is symbolic, but the real contest is over price and in vivo editing. Turning the technology into routine medicine demands the unglamorous work of cutting production cost and building reimbursement. Expect a few years of quiet groundwork behind the flashy breakthroughs.

FAQ

Q. Is CRISPR therapy editing embryos? A. Currently approved therapies edit the patient's own somatic cells and are not inherited. Germline (embryo) editing remains tightly restricted worldwide for ethical reasons.

Q. Is one treatment a permanent cure? A. Durable improvement is reported in sickle cell and similar diseases, but follow-up is still short for many, so "lifelong" claims need more time.

Q. Is it available in Japan? A. Casgevy approval and review are progressing in Japan, but eligible diseases and centers are limited, and the high price keeps real access narrow for now.